Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 352 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: PSA Clear all
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

NCT03896581
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
33
States / cities
Phoenix, Arizona • San Diego, California • Tustin, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 5:39 AM EDT
Active, not recruiting Phase 2 Interventional

Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

NCT01786265
View directory record Official record
Conditions
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Interventions
Abiraterone Acetate, Bicalutamide, Degarelix, Flutamide, Goserelin Acetate, Leuprolide Acetate, Nilutamide, Prednisone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 21, 2026, 5:39 AM EDT
Completed Phase 2 Interventional Results available

ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)

NCT00090363
View directory record Official record
Conditions
Prostate Cancer
Interventions
ZD4054 15 mg, Placebo, ZD4054 10 mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
7
States / cities
Tucson, Arizona • Los Angeles, California • Gainsville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Oct 21, 2026, 5:39 AM EDT
Completed Not applicable Interventional

High Dose-Rate Brachytherapy and/or Intensity Modulated External Beam Radiation Therapy for Prostate Cancer

NCT00243321
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
high dose-rate brachytherapy, intensity-modulated radiation therapy
Procedure
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Oct 21, 2026, 5:39 AM EDT
Not listed Not applicable Interventional

MR/TRUS Fusion Guided Prostate Biopsy

NCT04026763
View directory record Official record
Conditions
Prostate Disease, Elevated Prostate Specific Antigen, Family History of Prostate Cancer, Positive Digital Rectal Exam
Interventions
prostate biopsy, MR US Fusion Guided Prostate Biopsy, MR/TRUS Fusion Guided Prostate Biopsy
Procedure · Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Male only
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2019 · Synced Oct 21, 2026, 5:39 AM EDT
Completed Phase 2 Interventional

Study of CEP-701 in Treatment of Prostate Cancer

NCT00081601
View directory record Official record
Conditions
Prostate Cancer
Interventions
CEP-701
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2012 · Synced Oct 21, 2026, 5:39 AM EDT
Recruiting Phase 4 Interventional

Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test

NCT05629494
View directory record Official record
Conditions
Prostate Cancer, Prostate Inflammation, PSA
Interventions
Ibuprofen 400 mg, TID, PSA test
Drug · Diagnostic Test
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Chicago, Illinois • Albany, New York • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 18, 2024 · Synced Oct 21, 2026, 5:39 AM EDT
Completed Not applicable Interventional

Use of Telemedicine to Address 'Off Target' Symptoms in Psoriatic Arthritis (PsA)

NCT05631223
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Telemedicine
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 89 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 21, 2026, 5:39 AM EDT
Completed Phase 1 Interventional

Evaluation of Lithium and It's Effect on Clinically Localized Prostate Cancer

NCT02198859
View directory record Official record
Conditions
Prostate Cancer
Interventions
Lithium Carbonate
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 21, 2026, 5:39 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer

NCT00583024
View directory record Official record
Conditions
Hormone Refractory Prostate Cancer
Interventions
ADENOVIRUS/PSA VACCINE
Biological
Lead sponsor
David M Lubaroff
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Oct 21, 2026, 5:39 AM EDT
Completed Phase 2 Interventional Results available

Digoxin for Recurrent Prostate Cancer

NCT01162135
View directory record Official record
Conditions
Prostate Cancer
Interventions
Digoxin
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 21, 2026, 5:39 AM EDT
Completed Phase 1Phase 2 Interventional

A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer

NCT00286806
View directory record Official record
Conditions
Hormone Refractory Prostate Cancer
Interventions
AT-101
Drug
Lead sponsor
Ascenta Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
4
States / cities
Greenbrae, California • New Haven, Connecticut • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2010 · Synced Oct 21, 2026, 5:39 AM EDT
Completed Phase 2 Interventional Results available

Study of Acai Juice in Asymptomatic or Minimally Symptomatic Prostate Cancer Patients With Rising PSA

NCT01521949
View directory record Official record
Conditions
Prostate Cancer
Interventions
Acai Juice Product
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 21, 2026, 5:39 AM EDT
Completed Phase 3 Interventional Results available

Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)

NCT02662985
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
AIN457 (secukinumab), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Beverly Hills, California • Los Angeles, California • Wheaton, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Oct 21, 2026, 5:39 AM EDT
Withdrawn Phase 2 Interventional

Study of Metformin With Simvastatin for Men With Prostate Carcinoma

NCT01561482
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Metformin, Simvastatin
Drug
Lead sponsor
Nicholas Mitsiades
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2015 · Synced Oct 21, 2026, 5:39 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer

NCT00861471
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasms
Interventions
Docetaxel, Imatinib Mesylate
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2016 · Synced Oct 21, 2026, 5:39 AM EDT
Terminated Phase 2 Interventional

TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

NCT01194960
View directory record Official record
Conditions
Hormone Refractory Prostate Cancer
Interventions
Docetaxel, TroVax
Drug
Lead sponsor
Oxford BioMedica
Industry
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
7
States / cities
San Bernardino, California • Stanford, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 21, 2026, 5:39 AM EDT
Not listed Not applicable Interventional

Targeted Prostate Biopsy Using a Novel MRI-Ultrasound Fusion Device

NCT02524860
View directory record Official record
Conditions
Prostate Cancer
Interventions
Focal-Fusion Bx
Device
Lead sponsor
Focal Healthcare Inc.
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Sarasota, Florida
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 21, 2026, 5:39 AM EDT
Not listed Phase 2 Interventional

R-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of Recurrence

NCT00045123
View directory record Official record
Conditions
Prostate Cancer
Interventions
tarenflurbil, adjuvant therapy
Drug · Procedure
Lead sponsor
Myrexis Inc.
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
58
States / cities
Homewood, Alabama • Anchorage, Alaska • Fresno, California + 49 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 21, 2026, 5:39 AM EDT
Completed Not applicable Interventional

A Study of Grape Seed Extract in Asymptomatic Non-Metastatic Prostate Cancer Patients With Rising PSA

NCT03087903
View directory record Official record
Conditions
Prostate Cancer
Interventions
Grape Seed Extract
Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Aurora, Colorado • Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 21, 2026, 5:39 AM EDT
Active, not recruiting Phase 2 Interventional

Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery

NCT03541850
View directory record Official record
Conditions
PSA Level Greater Than 0.03, PSA Progression, Stage I Prostate Adenocarcinoma AJCC (American Joint Committee on Cancer ) v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
Interventions
Antiandrogen Therapy, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
Drug · Other · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 21, 2026, 5:39 AM EDT
Completed Phase 2 Interventional

Chemotherapy, Hormone Therapy, and Surgery to Remove the Prostate Gland in Patients With High Risk Prostate Cancer

NCT00108290
View directory record Official record
Conditions
Prostate Cancer
Interventions
Chemotherapy
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 80 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2008 · Synced Oct 21, 2026, 5:39 AM EDT
Recruiting Phase 4 Interventional

Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease

NCT07280702
View directory record Official record
Conditions
Psoriatic Arthritis (PsA)
Interventions
Deucravacitinib, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 21, 2026, 5:39 AM EDT
Active, not recruiting Not applicable Interventional

Diagnosing Clinically Significant Prostate Cancer In African American and White Men With Elevated PSA

NCT03234556
View directory record Official record
Conditions
Health Status Unknown, Elevated PSA
Interventions
Biopsy of Prostate, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, MRI Ultrasound Fusion Guided Biopsy
Procedure · Other · Diagnostic Test
Lead sponsor
University of Southern California
Other
Eligibility
40 Years and older · Male only
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 21, 2026, 5:39 AM EDT